BioSpace News Archive

BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, announces it has entered into an agreement with University of Carleton University (“Carleton”) for TD-0148A’s research in preclinical models of depression.

Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play IVD companies dedicated to transforming patient care, today announced that its new VITROS® Anti-SARS-CoV-2 Total 2 Antibody assay and VITROS® Anti-SARS-CoV-2 IgG 2 Antibody assay received CE Mark for the qualitative and semi-quantitative detection of COVID-19 antibodies.

ChromaDex Corp. (NASDAQ:CDXC) announced today it has appointed David L. Katz, MD, MPH, FACPM, FACP, FACLM - CEO of Diet ID, Inc, founder and former director of Yale University’s Yale-Griffin Prevention Research Center and past president of the American College of Lifestyle Medicine, to its Scientific Advisory Board (SAB).

AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and Chief Executive Officer, will participate in a panel discussion during the 33 rd Annual Roth Conference being held virtually from March 15-17, 2021. T

Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s three lead investigational gene therapies

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company has dosed its first patient in an open label Phase 1b/2 clinical trial to evaluate the safety, pharmacokinetic, and preliminary clinical activity of AVB-500, including progression free survival. The trial will enroll patients with advanced clear cell renal cell carcinoma (ccRCC) that have progressed on front-line tr

Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the appointment of Richard S. Casten, CPA, MBA as Chief Financial Officer. In this role, Mr. Casten will be responsible for leading and directing the financial activities of the Company. Mr. Casten brings to Baudax 25 years of diversified financial experience across pharmaceutical, Fortune 500 consumer products

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and its Solta Medical business, a global leader in the medical aesthetics market, today announced the U.S. launch of the Clear + Brilliant® Touch laser, the company’s next generation Clear + Brilliant® laser.

L7 Informatics, a leader in enterprise-scale digital transformation and automation of scientific processes in the life sciences and healthcare domains, announced that it closed its Series B financing round.

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Lisa Johnson-Pratt, M.D., Senior Vice President,